Hypoglycemia Risk May Be Lower With Liver-Targeted Rapid-Acting Insulin Formulation
Hepatic-directed vesicle insulin, a novel liver-targeted rapid-acting insulin formulation for type 1 diabetes, is noninferior to insulin lispro for improvement of HbA1c and is associated with a lower hypoglycemia risk in some patients.